• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

CRISPR Therapeutics' Base Can Support Further Price Gains

Let's look at the charts and indicators.
By BRUCE KAMICH
Aug 08, 2022 | 10:58 AM EDT
Stocks quotes in this article: CRSP

Gene editing company CRISPR Therapeutics (CRSP)  made a basing pattern in the January-July time frame and the indicators support the potential for further price gains. Let's check out the charts.

 
In this daily bar chart of CRSP, below, we can see that prices declined to a low in May but the base pattern looks like it has been evolving from February. The daily On-Balance-Volume (OBV) line bottomed in February and turned higher in March telling us of a shift from aggressive selling to aggressive buying.
 
Prices have been crisscrossing the 50-day moving average line since March. CRSP rallied above the 200-day line in early July and now the line is bottoming. The Moving Average Convergence Divergence (MACD) oscillator is above the zero line and poised to turn higher.
 
 
In this weekly Japanese candlestick chart of CRSP, below, we can see a bottom reversal pattern in early May. Prices have rallied above the 40-week moving average line which is starting to bottom.
 
The weekly OBV line shows some improvement from February. The MACD oscillator has been rising and is close to crossing above the zero line for an outright buy signal.
 
 
In this daily Point and Figure chart of CRSP, below, we can see a potential upside price target in the $103 area.
 
In this second Point and Figure chart of CRSP, below, we used weekly price data. Here the software suggests a target in the $121 area.
 
Bottom line strategy: Traders who went long following our July 1 update should continue to hold those positions. The $88-$102 area is our price target.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of theStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Biotechnology | Technology

More from Investing

Not Even the Mega-Cap Tech Stocks Could Hide From the Selling

James "Rev Shark" DePorre
Oct 3, 2023 4:37 PM EDT

Like or not, this is classic bear market action playing out.

McCormick Might Leave a Bad Taste in Investors' Mouths

Bruce Kamich
Oct 3, 2023 2:51 PM EDT

The charts don't look very appetizing for the spice company.

American Express: Leave Home Without It

Bruce Kamich
Oct 3, 2023 1:55 PM EDT

The charts show further declines ahead for the credit card company.

Costco: Are We Witnessing a Bull Trap?

Bruce Kamich
Oct 3, 2023 1:08 PM EDT

When one of the last holdouts of the S&P 500 turns down the selloff is in full gear.

Chasing Alpha With Alphabet

Ed Ponsi
Oct 3, 2023 12:35 PM EDT

I'm not the only one who likes the tech behemoth. Bill Ackman believes Alphabet will be a leader in AI for years to come.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:13 PM EDT BRUCE KAMICH

    8 Trading Rules from T. T. Hoyne

    You just read the header for this missive and prob...
  • 08:42 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How Elite Traders Make Big Profits
  • 02:58 PM EDT BRUCE KAMICH

    Classic Trading Rules From Bernard Baruch

    Bernard Baruch listed the rules (below) in his aut...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login